Why is Beta Bionics facing a securities class action lawsuit?

Investors allege Beta Bionics made misleading statements about the safety of its iLet Bionic Pancreas insulin pump and the scope and seriousness of FDA findings involving the device.

What are the allegations against Beta Bionics?

The complaint alleges Beta Bionics misrepresented FDA concerns involving its quality management system, device malfunctions, risk analysis, and unreported serious injuries.

What is the iLet Bionic Pancreas mentioned in the Beta Bionics lawsuit?

The iLet Bionic Pancreas is Beta Bionics’ automated insulin delivery system for people with diabetes and was the Company’s sole commercialized product during the alleged Class Period.

Why is the FDA Form 483 important to the Beta Bionics lawsuit?

Plaintiffs allege Beta Bionics characterized the FDA’s Form 483 observations as largely procedural when they involved broader product quality, safety, and compliance concerns.

What did Beta Bionics allegedly tell investors about the FDA inspection?

The complaint alleges Beta Bionics told investors the FDA’s concerns primarily involved criteria for determining which customer complaints required regulatory reporting.

What did Beta Bionics allegedly fail to disclose about the iLet insulin pump?

Plaintiffs allege the Company failed to adequately disclose problems involving device malfunctions, quality controls, risk analysis, and serious injuries that had not been properly reported.

Were serious injuries allegedly involved in the Beta Bionics FDA findings?

Yes. The complaint alleges some events Beta Bionics failed to report to the FDA involved serious injuries, contrary to representations that the events were minor.

What quality-control issues are alleged in the Beta Bionics lawsuit?

The complaint alleges FDA findings extended to Beta Bionics’ quality management system and its procedures for investigating and correcting known device malfunctions.

Why are FDA disclosures important to Beta Bionics investors?

FDA compliance can materially affect the safety, regulatory status, reputation, and commercial prospects of a medical device company and its products.

What are investors alleging about Beta Bionics’ public statements?

Plaintiffs allege Beta Bionics understated the seriousness of FDA concerns while continuing to make positive statements about the iLet’s safety, efficacy, and commercial success.

What is the deadline to seek lead plaintiff status in the Beta Bionics lawsuit?

Eligible investors seeking appointment as lead plaintiff must file a motion with the court by November 3, 2026.

What is a securities class action lawsuit?

A securities class action allows investors to collectively pursue claims involving alleged material misstatements, misleading disclosures, or omissions.

What does the class period mean in a securities class action?

The class period identifies the timeframe during which alleged misleading statements occurred and qualifying investors purchased or acquired securities.

What is a lead plaintiff in a securities class action?

A lead plaintiff is an investor appointed by the court to represent the proposed class and help oversee the litigation on behalf of class members.

Do investors need to become lead plaintiff to participate in a potential recovery?

No. Eligible investors generally do not need to serve as lead plaintiff to participate in a potential settlement or other recovery.

Beta Bionics, Inc. - Faruqi & Faruqi LLP

Beta Bionics, Inc.

Join Action

Case Details

Ticker BBNX

Class Period 07/30/2025 - 02/24/2026

Lead Plaintiff Deadline 11/03/2026

Days Left to Seek Lead Plaintiff

If you are a Beta Bionics investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Beta Bionics To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Beta Bionics between July 30, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) and reminds investors of the November 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the Company’s automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump (“iLet”). Throughout the Class Period, Defendants touted the safety, efficacy, and commercial success of the iLet, the Company’s sole commercialized product. After disclosing that the FDA had issued a Form 483 following an inspection of the Company’s manufacturing facility, Defendants repeatedly assured investors that the agency’s observations concerned only the Company’s criteria for deciding which customer complaints were reportable, that they reflected no underlying problem with the device, and that the complaints the Company would now be required to report were minor events of the kind requiring no medical intervention. In truth, the FDA’s findings reached the Company’s quality management system, its investigation and correction of known device malfunctions, and the risk analysis for the device itself, and the events the Company had failed to report included serious injuries. Defendants continued to reassure investors and to characterize the agency’s concerns as procedural even as further information emerged showing that the unreported events were far more serious than Defendants had represented and that the FDA’s objections were not confined to a difference in regulatory interpretation.

Lead Plaintiff Deadline: November 3, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

Beta Bionics, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify